Acetazolamide Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026 Acetazolamide is carbonic anhydrase inhibitor, used in adjuvant treatment of chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma, epilepsy, edema due to congestive heart failure, drug-induced edema, and acute mountain sickness in climbers. Acetazolamide promotes acclimatization to altitude, increases bicarbonate secretion by the kidneys, induces metabolic acidosis, and stimulates ventilation. Furthermore, according to the BMJ Journal, September 2012, acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily are more effective compared to placebo for preventing acute mountain sickness. In addition, acetazolamide 250 mg daily is the lowest effective dose to prevent acute mountain sickness. Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/ insight/request-sample/2396 The global acetazolamide market size was valued at US$ 183.2 Mn in 2017, and is expected to witness a CAGR of 4.8% during the forecast period (2018 – 2026). Market Dynamics Increasing prevalence of glaucoma and its risk factors among global population is propelling demand for acetazolamide during the forecast period. Moreover, acetazolamide is commonly used for preventing high altitude illness, this increases the utility of the drug. For instance, according to the International Journal of Advanced Medical and Health Research, 2015, glaucoma is seen to be the second major reason causing blindness among people across the world, followed by cataract. Furthermore, according to the BrightFocus Foundation, June 2017 data findings, over 3 million Americans suffer from glaucoma, out of which 2.7 million (aged 40 and older) are affected by its most common form, open-angle glaucoma. Also, high prevalence of eye disorder in the geriatric population and nutritional deficiency in the younger population due to changing food habits are other factors affecting the health of the people globally, which might lead to boost growth of acetazolamide market. Acetazolamide capsule taken once a day by patients with chronic glaucoma offers a substantial pressure-lowering effect, which lasts at least 23 hours. Report includes chapters which deeply display the following deliverable about industry : • Acetazolamide Market Research Objective and Assumption • Acetazolamide Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Acetazolamide Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Acetazolamide Market, By Regions • Acetazolamide Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Acetazolamide Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Acetazolamide Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Acetazolamide Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Extended Application of Acetazolamide in Various Treatment Modalities is expected to Drive Market Growth during the Forecast Period Acetazolamide is used to prevent high altitude illness in most people, which is characterized by headache, nausea, vomiting, and tiredness (often called acute mountain sickness), but may affect the brain or the lungs in different individuals. As per the study published in Cochrane Journal, in June 2017, acetazolamide is an effective and better treatment for the prevention of acute high altitude illness (HAI) in dosages of 250 to 750 mg/day, when compared to a placebo. Acetazolamide prevents acute mountain sickness and has fewer side effects than alternative drugs such as dexamethasone. According to BMJ journal, May 2018, prescribing acetazolamide for travel is an optional service and not included in the general practitioner’s contract in the U.K. Browse Complete Report For More Information @ http://bit.ly/2ZvzHEY Key players operating in the acetazolamide market include Teva Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage Laboratories Inc., Novast Laboratories Ltd., Cadila Healthcare Inc.), Lannett Company, Inc., Strides Shasun Limited, and X-GEN Pharmaceutical Industries Ltd., Pharmaceuticals Inc., Nostrum (Zydus Pharmaceuticals (USA) Pharmaceuticals, Inc. About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Acetazolamide is an enzyme inhibitor, which acts specifically on carbonic anhydrase. Acetazolamide, sold under the trade name Diamox, is used to treat glaucoma, altitude sickness, epilepsy, fluid retention, heart failure, and seizures.
© Copyright 2024 Paperzz
